tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Robyn Karnauskas, 320 are a BUY (84.88%), 56 are a HOLD (14.85%), 1 are a SELL (0.27%).
Analyst Robyn Karnauskas, carries an average stock price target met ratio of 52.28% that have a potential upside of 39.64% achieved within 364 days. Previously, Robyn Karnauskas worked at TRUIST.
Robyn Karnauskas’s has documented 767 price targets and ratings displayed on 46 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on LLY, Eli Lilly and Company at 19-Nov-2025.
Analyst best performing recommendations are on DRNA (DICERNA PHARMACEUTICALS).
The best stock recommendation documented was for DRNA (DICERNA PHARMACEUTICALS) at 11/18/2019. The price target of $24 was fulfilled within 1 day with a profit of $2.61 (12.2%) receiving and performance score of 122.02.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 25-Feb-2026
$260
$29.89 (12.99%)
$220
15 days ago
(25-Feb-2026)
5/6 (83.33%)
$31.56 (13.82%)
168
Hold Since 07-Jan-2026
$230
$-0.11 (-0.05%)
$240
1 months 7 days ago
(05-Feb-2026)
1/2 (50%)
$10.98 (5.01%)
8
Buy Since 24-Jan-2022
$270
$39.89 (17.34%)
$269
1 months 7 days ago
(05-Feb-2026)
16/20 (80%)
$50.98 (23.28%)
510
Hold Since 14-May-2025
$230
$-0.11 (-0.05%)
$235
1 months 13 days ago
(27-Jan-2026)
17/18 (94.44%)
$6.07 (2.71%)
279
Buy Since 16-Oct-2020
$260
$29.89 (12.99%)
$235
4 months 9 days ago
(03-Nov-2025)
15/16 (93.75%)
$49.73 (23.65%)
463
Which stock is Robyn Karnauskas is most bullish on?
What Year was the first public recommendation made by Robyn Karnauskas?
